查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1702062

中枢神经系统治疗市场报告（按疾病、应用和地区）2025-2033

Central Nervous System Therapeutics Market Report by Disease, Application, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 136 Pages | 商品交期: 2-3个工作天内

价格

2024 年全球中枢神经系统 (CNS) 治疗市场规模达 1,487 亿美元。展望未来， IMARC Group预计到 2033 年市场规模将达到 2,573 亿美元，2025-2033 年期间的成长率 (CAGR) 为 5.64%。大众中神经和精神疾病的盛行率不断上升、远距医疗和远距医疗服务的兴起以及贸易协定和伙伴关係的增加是推动市场成长的关键因素。

中枢神经系统 (CNS) 治疗学专注于治疗和管理影响构成中枢神经系统的大脑和脊髓的疾病。这些疾病包括神经退化性疾病，如阿兹海默症和帕金森氏症，以及精神疾病，如忧郁症和焦虑症。它们还涵盖急性病症，包括创伤性脑损伤和中风。治疗领域非常广泛，包括各种方法，例如药物干预、外科手术以及基因治疗等较新的治疗方法。药物可以包括抗忧郁药、抗精神病药或专门针对神经通路的药物。在神经科学和生物技术进步的推动下，该领域的研究不断发展。

中枢神经系统 (CNS) 治疗产业的主要市场驱动力之一是全球神经和精神疾病盛行率的上升。由于人口老化、生活方式改变和环境压力等因素，阿兹海默症、帕金森氏症、忧郁症和焦虑症等疾病变得越来越普遍。随着需要中枢神经系统治疗的患者数量不断增加，市场潜力不断扩大，使其成为一个有吸引力的投资和创新领域。同时，远距医疗和远距医疗服务的兴起被证明是市场成长的重要动力。 COVID-19 疫情加速了远距医疗的采用，而且这种趋势可能会持续下去。远距医疗服务使患者更方便地寻求医疗建议并获得中枢神经系统疾病的处方，而无需亲自预约。这种可近性的提高对于偏远地区的人们尤其有益，扩大了中枢神经系统治疗的患者基础。此外，监管机构越来越愿意加快审批创新中枢神经系统治疗药物，特别是那些解决未满足医疗需求的药物。因此，它正在为市场做出贡献。此外，全球化往往促进贸易协定和伙伴关係的形成，为中枢神经系统治疗产品提供更精简的分销网络，并创造积极的市场前景。

中枢神经系统（CNS）治疗市场趋势/驱动因素：

药物研发的技术进步

科技的快速进步是中枢神经系统治疗产业发展的关键驱动力。传统的药物研发方法正在透过人工智慧 (AI)、机器学习和巨量资料分析等技术得到增强。这些技术有助于更快地识别潜在的候选药物，从而加快药物开发的进程。高通量筛选方法也变得更加复杂，使得研究人员能够在更短的时间内评估数千种化合物。生物资讯学工具和计算模型越来越多地用于在分子层面上了解疾病途径，有助于开发有针对性的治疗方法。这些技术进步大大减少了将新型中枢神经系统治疗药物推向市场的时间和成本，为产业发展提供了强劲动力。

公众意识和医疗保健基础设施

近年来，大众对心理健康和神经系统疾病的认识显着提高。这种认知的提高促进了早期诊断和治疗，进而推动了对中枢神经系统治疗的需求。此外，政府和医疗保健组织越来越认识到心理健康的重要性，从而促进了更好的医疗保健基础设施和政策，促进了中枢神经系统药物的开发和分销。在许多已开发国家，保险覆盖范围已扩大到包括神经和精神疾病的治疗，使更广泛的人群能够获得治疗。神经病学诊所和復健中心等专科医疗机构的兴起为中枢神经系统治疗增加了另一层市场潜力。随着医疗保健基础设施的不断改善，有效且创新的中枢神经系统治疗市场也不断扩大。

研发投入不断增加

研究与开发 (R&D) 是中枢神经系统治疗产业的支柱，而该领域不断增长的投资是重要的市场驱动力。此外，製药公司也投入大量资源进行研发活动，通常与学术机构和研究组织合作。这种伙伴关係有利于共享专业知识和财政资源，从而加速发展进程。此外，政府补助、创投基金和公私合作伙伴关係在支持研发工作方面也发挥越来越重要的作用。这种协作环境带来了突破性的发现，包括针对性治疗和治疗中枢神经系统疾病的个人化医疗方法。高投资回报的承诺，加上对有效治疗的持续需求，确保研发资金仍然是中枢神经系统治疗产业成长的强大动力。

目录

第一章：前言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 次要来源
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：简介

  • 概述
  • 主要行业趋势

第五章：全球中枢神经系统（CNS）治疗市场

  • 市场概览
  • 市场表现
  • COVID-19的影响
  • 市场预测

第六章：市场区隔：依疾病

  • 神经退化性疾病
    • 关键部分
      • 阿兹海默症
      • 帕金森氏症
      • 多发性硬化症
      • 亨廷顿舞蹈症
      • 肌萎缩侧索硬化症
      • 其他的
  • 神经血管疾病
  • 中枢神经系统创伤
  • 心理健康
    • 关键部分
      • 焦虑症
      • 癫痫
      • 情绪障碍
      • 精神病性障碍
      • 其他的
  • 传染病
  • 中枢神经系统癌症
  • 其他的

第七章：市场区隔：依应用

  • 医院
  • 诊所
  • 居家护理
  • 其他的

第八章：市场区隔：依地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场区隔：依国家

第九章：SWOT分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 10 章：价值链分析

第 11 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 12 章：价格分析

第 13 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • AstraZeneca plc
    • Biogen Inc.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche AG (Roche Holding)
    • H. Lundbeck A/S
    • Merck & Co. Inc.
    • Neurocrine Biosciences Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Ltd.
Product Code: SR112025A6114

The global central nervous system (CNS) therapeutics market size reached USD 148.7 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 257.3 Billion by 2033, exhibiting a growth rate (CAGR) of 5.64% during 2025-2033. The growing prevalence of neurological and psychiatric disorders among the masses, the rise in telehealth and telemedicine services, and the increase in trade agreements and partnerships are among the key factors driving the market growth.

Central nervous system (CNS) therapeutics focus on the treatment and management of disorders affecting the brain and spinal cord, which make up the central nervous system. These disorders can range from neurodegenerative diseases, such as Alzheimer's and Parkinson's to psychiatric conditions such as depression and anxiety. They also cover acute conditions, including traumatic brain injuries and strokes. The treatment landscape is vast and includes various approaches, such as pharmacological interventions, surgical procedures, and newer modalities, including gene therapy. Medications can consist of antidepressants, antipsychotics, or drugs specifically designed to target neural pathways. Research in this field is continually evolving, driven by advancements in neuroscience and biotechnology.

One of the primary market drivers for the central nervous system (CNS) therapeutics industry is the rising prevalence of neurological and psychiatric disorders globally. Conditions such as Alzheimer's, Parkinson's, depression, and anxiety are becoming increasingly common due to factors, such as an aging population, lifestyle changes, and environmental stressors. With an increasing number of patients requiring CNS therapeutics, the market potential continues to expand, making it an attractive area for investment and innovation. Along with this, the rise in telehealth and telemedicine services is proving to be a significant driver in the market growth. The COVID-19 pandemic has accelerated the adoption of remote healthcare, and this trend is likely to continue. Telehealth services make it more convenient for patients to seek medical advice and obtain prescriptions for CNS disorders without the need for physical appointments. This increased accessibility is particularly beneficial for those in remote areas, broadening the patient base for CNS therapeutics. In addition, regulatory agencies are showing an increased willingness to fast-track the approval of innovative CNS therapeutic drugs, particularly those addressing unmet medical needs. Therefore, it is contributing to the market. Moreover, trade agreements and partnerships are often facilitated by globalization, providing a more streamlined distribution network for CNS therapeutic products, and creating a positive market outlook.

Central Nervous System (CNS) Therapeutics Market Trends/Drivers:

Technological Advancements in Drug Discovery

The rapid advancements in technology have been a crucial driver for the CNS therapeutics industry. Traditional methods of drug discovery are being augmented by technologies such as artificial intelligence (AI), machine learning, and big data analytics. These technologies help in quicker identification of potential drug candidates, thereby speeding up the process of drug development. High-throughput screening methods have also become more sophisticated, allowing researchers to evaluate thousands of compounds in a shorter time frame. Bioinformatics tools and computational models are increasingly used for understanding disease pathways at the molecular level, aiding in the development of targeted therapies. These technological strides have significantly reduced the time and cost associated with bringing a new CNS therapeutic drug to market, providing a robust impetus for industry growth.

Public Awareness and Healthcare Infrastructure

Public awareness about mental health and neurological disorders has grown significantly in recent years. This increased awareness has led to early diagnosis and treatment, subsequently driving the demand for CNS therapeutics. Furthermore, governments and healthcare organizations are increasingly recognizing the importance of mental health, leading to better healthcare infrastructure and policies that facilitate the development and distribution of CNS drugs. In many developed countries, insurance coverage has expanded to include treatments for neurological and psychiatric disorders, making therapies more accessible to a broader population. The rise in specialized healthcare facilities, such as neurology clinics and rehabilitation centers, adds another layer of market potential for CNS therapeutics. As healthcare infrastructure continues to improve, so does the market for effective and innovative CNS treatments.

Growing Investment in Research and Development

Research and development (R&D) form the backbone of the CNS therapeutics industry, and growing investment in this area serves as a substantial market driver. Additionally, pharmaceutical companies are dedicating significant resources to R&D activities, often in collaboration with academic institutions and research organizations. Such partnerships facilitate the sharing of expertise and financial resources, thereby expediting the development process. In addition, government grants, venture capital funding, and public-private partnerships are also playing an increasing role in supporting R&D efforts. This collaborative environment has led to groundbreaking discoveries, including targeted therapies and personalized medicine approaches for treating CNS disorders. The promise of high returns on investment, coupled with the ever-present demand for effective treatments, ensures that R&D funding remains a strong driver for the growth of the CNS Therapeutics industry.

Central Nervous System (CNS) Therapeutics Industry Segmentation:

Breakup by Disease:

  • Neurodegenerative Diseases
  • Alzheimer's Disease
  • Parkinson's Disease
  • Multiple Sclerosis
  • Huntington's Disease
  • Amyotrophic Lateral Sclerosis
  • Others
  • Neurovascular Diseases
  • CNS Trauma
  • Mental Health
  • Anxiety Disorders
  • Epilepsy
  • Mood Disorders
  • Psychotic Disorders
  • Others
  • Infectious Diseases
  • CNS Cancer
  • Others

Neurodegenerative Diseases represent the largest market share

The rising incidence of neurodegenerative diseases, such as Alzheimer's, Parkinson's, and Multiple Sclerosis is a significant market driver in the central nervous system (CNS) Therapeutics industry. As the global population ages, the prevalence of these conditions is expected to escalate, increasing the demand for effective treatments. Along with this, the socioeconomic burden these diseases place on healthcare systems and families is pushing both public and private sectors to invest heavily in research and development. Technological advancements, such as biomarker identification and gene editing, are accelerating the pace of drug discovery for neurodegenerative conditions, attracting further investment. Additionally, government initiatives and regulatory support, mainly fast-track approvals and grants, provide an impetus for pharmaceutical companies to develop innovative solutions. In addition, the growing public awareness and educational campaigns around neurodegenerative diseases are also contributing to market growth by encouraging early diagnosis and treatment. All these factors collectively create a conducive environment for the expansion of the CNS Therapeutics market in the domain of neurodegenerative diseases.

Breakup by Application:

  • Hospital
  • Clinic
  • Homecare
  • Others

The role of hospitals as a primary point of care for acute and chronic neurological conditions is a significant market driver in the central nervous system (CNS) therapeutics industry. Hospitals are often equipped with advanced diagnostic tools and treatment facilities, making them essential for managing complex CNS disorders. As cases of traumatic brain injuries, strokes, and emergency psychiatric episodes continue to rise, the need for specialized CNS therapeutics within hospital settings becomes increasingly crucial. The demand is further fueled by the growing number of specialized neurology departments and centers of excellence in hospitals, which require a consistent supply of CNS medications and treatments. Additionally, hospitals are key sites for clinical trials, accelerating the adoption of innovative CNS therapies.

On the contrary, the rising trend towards homecare for managing chronic and post-acute conditions is significantly influencing the Central Nervous System (CNS) therapeutics industry. As technological advancements make remote monitoring and telehealth more viable, many patients prefer receiving care in the comfort of their homes. Homecare is especially relevant for the elderly population and patients with neurodegenerative disorders who may find frequent hospital visits cumbersome. In addition, the availability of easy-to-administer medications and therapies suitable for home use is driving demand in this segment. Moreover, healthcare models are shifting towards more patient-centric approaches, further encouraging the adoption of homecare solutions. These trends not only broaden the consumer base but also open new channels for the distribution of CNS therapeutics, boosting overall market growth.

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

North America exhibits a clear dominance, accounting for the largest central nervous system (CNS) therapeutics market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America exhibited the largest market segment.

The central nervous system (CNS) therapeutics industry in North America is driven by the high prevalence of CNS-related disorders, including mental health conditions, neurodegenerative diseases, and acute neurological issues. According to the Centers for Disease Control and Prevention (CDC), one in five American adults experiences mental illness each year. Furthermore, an aging population in the region significantly contributes to the increased incidence of age-related neurodegenerative diseases such as Alzheimer's and Parkinson's.

In addition, technological innovation is another significant driver, with North America often leading in the development of advanced treatments, including gene therapies and neural implants. The region also benefits from strong regulatory support, with agencies providing fast-track approvals for innovative CNS drugs. Moreover, robust healthcare infrastructure, including advanced hospitals and a growing focus on telehealth services, facilitates easier access to treatments. Furthermore, substantial investment in research and development, both from public and private sectors, furthers innovation and the speed-to-market for new CNS therapies, collectively making North America a dynamic market for CNS therapeutics.

Competitive Landscape:

The key players are allocating significant resources to advance their understanding of CNS disorders, uncover novel treatment approaches, and develop new therapeutic agents. This involves conducting clinical trials, and preclinical studies, and leveraging cutting-edge technologies to identify potential drug candidates. Along with this, brands are leveraging advanced techniques, such as high-throughput screening, molecular modeling, and genetics to discover compounds with the potential to modulate CNS-related targets. These efforts aim to identify effective drug candidates that can address specific neurological conditions. In addition, the growing focus on personalized medicine within the CNS therapeutics field is positively influencing the market. Apart from this, companies are particularly focused on neurodegenerative diseases such as Alzheimer's, Parkinson's, and ALS. Research efforts are aimed at unraveling the underlying mechanisms of these diseases and developing disease-modifying treatments, which act as another growth-inducing factor. Furthermore, the escalating number of collaborations with research institutions, academia, and other industry players to develop new therapeutic approaches is contributing to the market.

The market research report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • AstraZeneca plc
  • Biogen Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG (Roche Holding)
  • H. Lundbeck A/S
  • Merck & Co. Inc.
  • Neurocrine Biosciences Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report

  • 1.What was the size of the global Central Nervous System (CNS) therapeutics market in 2024?
  • 2.What is the expected growth rate of the global Central Nervous System (CNS) therapeutics market during 2025-2033?
  • 3.What are the key factors driving the global Central Nervous System (CNS) therapeutics market?
  • 4.What has been the impact of COVID-19 on the global Central Nervous System (CNS) therapeutics market?
  • 5.What is the breakup of the global Central Nervous System (CNS) therapeutics market based on the disease?
  • 6.What are the key regions in the global Central Nervous System (CNS) therapeutics market?
  • 7.Who are the key players/companies in the global Central Nervous System (CNS) therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Central Nervous System (CNS) Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Disease

  • 6.1 Neurodegenerative Diseases
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Alzheimer's Disease
      • 6.1.2.2 Parkinson's Disease
      • 6.1.2.3 Multiple Sclerosis
      • 6.1.2.4 Huntington's Disease
      • 6.1.2.5 Amyotrophic Lateral Sclerosis
      • 6.1.2.6 Others
    • 6.1.3 Market Forecast
  • 6.2 Neurovascular Diseases
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 CNS Trauma
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Mental Health
    • 6.4.1 Market Trends
    • 6.4.2 Key Segments
      • 6.4.2.1 Anxiety Disorders
      • 6.4.2.2 Epilepsy
      • 6.4.2.3 Mood Disorders
      • 6.4.2.4 Psychotic Disorders
      • 6.4.2.5 Others
    • 6.4.3 Market Forecast
  • 6.5 Infectious Diseases
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 CNS Cancer
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Others
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast

7 Market Breakup by Application

  • 7.1 Hospital
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Clinic
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Homecare
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia-Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 AstraZeneca plc
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 Biogen Inc.
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
      • 13.3.2.4 SWOT Analysis
    • 13.3.3 Eli Lilly and Company
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
      • 13.3.3.4 SWOT Analysis
    • 13.3.4 F. Hoffmann-La Roche AG (Roche Holding)
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 SWOT Analysis
    • 13.3.5 H. Lundbeck A/S
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 Financials
      • 13.3.5.4 SWOT Analysis
    • 13.3.6 Merck & Co. Inc.
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
      • 13.3.6.4 SWOT Analysis
    • 13.3.7 Neurocrine Biosciences Inc.
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
      • 13.3.7.4 SWOT Analysis
    • 13.3.8 Novartis AG
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 Financials
      • 13.3.8.4 SWOT Analysis
    • 13.3.9 Pfizer Inc.
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials
      • 13.3.9.4 SWOT Analysis
    • 13.3.10 Sanofi S.A.
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
      • 13.3.10.3 Financials
      • 13.3.10.4 SWOT Analysis
    • 13.3.11 Takeda Pharmaceutical Company Limited
      • 13.3.11.1 Company Overview
      • 13.3.11.2 Product Portfolio
      • 13.3.11.3 Financials
      • 13.3.11.4 SWOT Analysis
    • 13.3.12 Teva Pharmaceutical Industries Ltd.
      • 13.3.12.1 Company Overview
      • 13.3.12.2 Product Portfolio
      • 13.3.12.3 Financials
      • 13.3.12.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Central Nervous System Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Central Nervous System Therapeutics Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Central Nervous System Therapeutics Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Central Nervous System Therapeutics Market: Breakup by Disease (in %), 2024
  • Figure 5: Global: Central Nervous System Therapeutics Market: Breakup by Application (in %), 2024
  • Figure 6: Global: Central Nervous System Therapeutics Market: Breakup by Region (in %), 2024
  • Figure 7: Global: Central Nervous System Therapeutics (Neurodegenerative Diseases) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 8: Global: Central Nervous System Therapeutics (Neurodegenerative Diseases) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 9: Global: Central Nervous System Therapeutics (Neurovascular Diseases) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Central Nervous System Therapeutics (Neurovascular Diseases) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Central Nervous System Therapeutics (CNS Trauma) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Central Nervous System Therapeutics (CNS Trauma) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Central Nervous System Therapeutics (Mental Health) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Central Nervous System Therapeutics (Mental Health) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Central Nervous System Therapeutics (Infectious Diseases) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Central Nervous System Therapeutics (Infectious Diseases) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Central Nervous System Therapeutics (CNS Cancer) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Central Nervous System Therapeutics (CNS Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Central Nervous System Therapeutics (Other Diseases) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Central Nervous System Therapeutics (Other Diseases) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Central Nervous System Therapeutics (Hospital) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Central Nervous System Therapeutics (Hospital) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Central Nervous System Therapeutics (Clinic) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Central Nervous System Therapeutics (Clinic) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Global: Central Nervous System Therapeutics (Homecare) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Global: Central Nervous System Therapeutics (Homecare) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Global: Central Nervous System Therapeutics (Other Applications) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: Global: Central Nervous System Therapeutics (Other Applications) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: North America: Central Nervous System Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: North America: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: United States: Central Nervous System Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: United States: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: Canada: Central Nervous System Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: Canada: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: Asia-Pacific: Central Nervous System Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: Asia-Pacific: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: China: Central Nervous System Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: China: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: Japan: Central Nervous System Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: Japan: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: India: Central Nervous System Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: India: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: South Korea: Central Nervous System Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: South Korea: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: Australia: Central Nervous System Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: Australia: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: Indonesia: Central Nervous System Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: Indonesia: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: Others: Central Nervous System Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: Others: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: Europe: Central Nervous System Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: Europe: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: Germany: Central Nervous System Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: Germany: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: France: Central Nervous System Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: France: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: United Kingdom: Central Nervous System Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: United Kingdom: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: Italy: Central Nervous System Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: Italy: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: Spain: Central Nervous System Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: Spain: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: Russia: Central Nervous System Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: Russia: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: Others: Central Nervous System Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: Others: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: Latin America: Central Nervous System Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: Latin America: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: Brazil: Central Nervous System Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: Brazil: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: Mexico: Central Nervous System Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: Mexico: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: Others: Central Nervous System Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 74: Others: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Middle East and Africa: Central Nervous System Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 76: Middle East and Africa: Central Nervous System Therapeutics Market: Breakup by Country (in %), 2024
  • Figure 77: Middle East and Africa: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 78: Global: Central Nervous System Therapeutics Industry: SWOT Analysis
  • Figure 79: Global: Central Nervous System Therapeutics Industry: Value Chain Analysis
  • Figure 80: Global: Central Nervous System Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Central Nervous System Therapeutics Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Central Nervous System Therapeutics Market Forecast: Breakup by Disease (in Million USD), 2025-2033
  • Table 3: Global: Central Nervous System Therapeutics Market Forecast: Breakup by Application (in Million USD), 2025-2033
  • Table 4: Global: Central Nervous System Therapeutics Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 5: Global: Central Nervous System Therapeutics Market: Competitive Structure
  • Table 6: Global: Central Nervous System Therapeutics Market: Key Players